TRUL: Schedule III Shift And Repriced P E Multiple Will Drive Upside

Analysts raised their price target for Trulieve Cannabis to CA$15.26 from CA$14.95, citing updated assumptions based on higher modeled revenue growth, stronger profit margins, and a more moderate future P/E multiple.

Analyst Commentary

Street research on the broader equity market has included several cautious revisions and lower price targets, which can help frame how bearish analysts might approach a stock like Trulieve Cannabis. While the referenced reports focus on other companies, the themes highlight concerns that can also matter for cannabis names, especially around valuation, growth durability, and execution.

For Trulieve, the recent price target increase to CA$15.26 is presented alongside a more moderate future P/E multiple. That kind of adjustment suggests analysts are conscious of not overpaying for modeled revenue and margins, particularly in sectors where regulatory, funding, and competitive risks can be material.

Bearish Takeaways

Bearish analysts have been willing to cut price targets even when core forecasts are described as largely unchanged. This signals a tighter stance on what they are prepared to pay for growth and could also influence how they think about Trulieve’s valuation risk.
Several research notes in other sectors reference lower price targets after model updates that incorporate acquisitions, geographic units, or product changes. This shows that execution complexity is a point of concern that could similarly lead to more conservative views on Trulieve if integration or expansion efforts do not run smoothly.
Some bearish calls highlight that even when companies report results that meet or slightly beat expectations, updated assumptions can still lead to reduced targets. This underscores that Trulieve could face downside risk if its revenue mix, cost base, or capital allocation plans shift in ways that make future earnings quality less certain.
Where analysts describe valuations as attractive while still trimming targets, it points to a willingness to acknowledge opportunity while capping upside expectations. This may translate to a more cautious ceiling on Trulieve’s potential upside if sector wide regulatory or funding risks remain in focus.

For you as an investor, the key takeaway is that even when the headline move is a higher target, the supporting assumptions matter. Changes to growth, margin, and P/E inputs can reflect quiet caution as much as confidence, and that is worth keeping in mind when weighing Trulieve against other opportunities in the cannabis sector.

What’s in the News

The Trump administration is expected to reclassify cannabis, a move that could affect federal treatment of the sector and companies like Trulieve that operate in regulated markets (Axios).
A large review in The Lancet reports limited evidence that cannabis based medicines help most mental health and substance use disorders, which could influence how investors think about medical use cases that include Trulieve’s addressable market (Reuters).
Trulieve continues its Florida expansion with new medical dispensaries opened in Tallahassee, Boca Raton, Lutz, DeLand, Lake Wales, and Fort Myers, all offering extended hours, online ordering, and in store pickup.
Across these new Florida locations, Trulieve is featuring a broad mix of in house brands such as Co2lors, Cultivar Collection, Modern Flower, Momenta, Roll One, Sweet Talk, and Alchemy, alongside partner brands like Alien Labs, Khalifa Kush, and Sunshine Cannabis, which are described as exclusive to Trulieve in the state.
Trulieve closed a private placement on February 6, 2026 that involved 11 investors, following an earlier announcement that it would receive US$13,500,000 in funding via convertible debt under Regulation D.

Valuation Changes

Fair Value: CA$15.26 vs. CA$14.95 previously, a small upward move in the modeled fair value estimate.
Discount Rate: Held essentially flat at 6.44%, indicating no material change in the required return assumption.
Revenue Growth: Dollar revenue growth input adjusted from 1.28% to 1.33%, a modest shift in the top line outlook used in the model.
Net Profit Margin: Dollar net profit margin assumption increased from 3.81% to 7.72%, indicating a meaningfully higher margin profile in the updated model.
Future P/E: Future P/E multiple reduced from 857x to 27.8x, a substantial reset in how much earnings investors are assumed to be willing to pay for.

6 views

Key Takeaways

Reliance on policy reform and concentrated exposure to select states make the company vulnerable to regulatory, legislative, and competitive risks impacting future growth.
Ongoing price compression, economic pressures, and slow federal progress threaten margins, profitability, and the ability to sustain premium positioning.
Heavy dependence on Florida and industry price pressures threaten margins and growth, while high debt and uncertain expansion opportunities constrain future financial flexibility.

Catalysts

About Trulieve Cannabis

Operates as a cannabis retailer.What are the underlying business or industry changes driving this perspective?

While Trulieve benefits from momentum in reform initiatives at the state level and could see an expanded addressable market if adult-use legalization advances in Florida and Pennsylvania, the outcome and timing of these policy changes remain highly uncertain. Any delay or failure in legislative efforts would limit market growth and impede potential revenue upside in key states.
Although the company's scale, vertical integration, and strong gross margins have enabled it to outperform peers and withstand price compression thus far, ongoing consumer wallet pressure and shifts toward value-tier products threaten to erode overall revenue per customer and compress gross margins over time, especially if broader economic conditions deteriorate.
While there is optimism that federal rescheduling, banking reform, or future regulatory normalization could reduce punitive tax burdens and operating costs for legal cannabis operators, the persistent risk of slow or stalled federal action could keep Trulieve exposed to high 280E taxes and legacy compliance costs, continuing to suppress net profits and limit retained earnings.
Even as Trulieve looks to leverage its cash flow for opportunistic M&A or expansion into newly legalized markets such as Texas, heavy reliance on a limited number of core states-most notably Florida-concentrates regulatory and competitive risk. If Florida market dynamics mature or new competitors capture share, it could cause revenue stagnation or sudden volatility with little offset from other regions.
While the company is investing in product innovation and securing distribution deals, ongoing national trends of price compression and product commoditization due to oversupply and shifting consumer preferences could make it increasingly difficult to protect premium pricing, putting sustained pressure on gross margin and EBITDA if volume growth fails to compensate for lower average selling prices.

Trulieve Cannabis Earnings and Revenue Growth

Trulieve Cannabis Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Trulieve Cannabis compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Trulieve Cannabis's revenue will grow by 1.3% annually over the next 3 years.
The bearish analysts are not forecasting that Trulieve Cannabis will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Trulieve Cannabis's profit margin will increase from -9.4% to the average CA Pharmaceuticals industry of 7.7% in 3 years.
If Trulieve Cannabis's profit margin were to converge on the industry average, you could expect earnings to reach $94.8 million (and earnings per share of $0.48) by about April 2029, up from -$110.8 million today.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 27.8x on those 2029 earnings, up from -14.2x today. This future PE is greater than the current PE for the CA Pharmaceuticals industry at 14.7x.
The bearish analysts expect the number of shares outstanding to grow by 0.64% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.44%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Trulieve's near-term and medium-term revenues face headwinds from persistent price compression and tightening consumer budgets, as indicated by stable overall revenue despite increasing retail traffic and unit sales, which leads to lower average transaction values and pressured gross margins.
The company's continued heavy reliance on the Florida market, in both advocacy and financial investment for future adult-use ballot initiatives, exposes revenue and growth prospects to significant risk if legislative or voter approval is delayed or fails, given the high impact the Florida market has on overall financials.
While Trulieve currently maintains best-in-class margins, the management's acknowledgment of margin fluctuation and seasonality, alongside increased promotional activity and product mix shifts, highlights a risk of future margin erosion as price competition intensifies and consumer trends favor value products, which would negatively impact net margins.
Despite strong current cash reserves, Trulieve's substantial debt burden-including $478 million in debt and the need to refinance a significant portion of $368 million in senior secured notes-could limit capital allocation flexibility, drive up interest expense, and constrain net earnings and free cash flow if refinancing costs rise or cash flow slows.
Long-term growth opportunities through geographic expansion and M&A remain uncertain, with management noting that attractive opportunities are still in early stages and that industry consolidation or delayed state-level legalization (especially in large markets like Texas and Georgia) could delay or cap revenue growth and limit earnings potential over the next several years.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Trulieve Cannabis is CA$15.26, which represents up to two standard deviations below the consensus price target of CA$20.36. This valuation is based on what can be assumed as the expectations of Trulieve Cannabis's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CA$28.49, and the most bearish reporting a price target of just CA$15.26.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $94.8 million, and it would be trading on a PE ratio of 27.8x, assuming you use a discount rate of 6.4%.
Given the current share price of CA$11.15, the analyst price target of CA$15.26 is 26.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Trulieve Cannabis?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Regulatory Hurdles Will Limit Florida Expansion But Spark Recovery